AltStreet
SEC filing record
Primary Source · SEC.gov

Bain Capital Life Sciences Fund IV, L.P.

Fund Vehicle2024 vintage506(b), 3(c)
Latest signalNew Form D filerForm D · 2024-03-28Last filing 2024-03-28

Raised

Pre-open

Investors

—

Min Invest

None stated

Is this your company or fund? Claim this page free.

Claim free

AltStreet Analysis

·

Generated from EDGAR primary sources

Bain Capital Life Sciences Fund IV, L.P. is a Delaware limited partnership filing under Rule 506(b) and Section 3(c) exemptions. This is a pre-open filing with no disclosed capital raised, investor count, or minimum investment. The fund is managed by executive officers Adam Koppel, Jeffrey Schwartz, Ricky Sun, and Andrew Hack, and represents Bain Capital's fourth life sciences-focused vehicle.

This pooled investment fund targets longevity and biotech opportunities, a category typically structured as institutional limited partnerships with high minimum commitments. The 506(b) exemption permits general solicitation restrictions common among established fund managers with existing investor relationships, consistent with traditional life sciences venture capital structures.

Data Flags

generalPre-open filing for a Fund IV vehicle from an established institutional sponsor; suggests anticipated substantial institutional raise not yet commenced

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001996979
Entity NameBain Capital Life Sciences Fund IV, L.P.
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer Address200 Clarendon Street, Boston, MA 02116
Phone(617) 516-2000
Industry / Fund TypePooled Investment Fund · Private Equity Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled Investment Fund
First Sale DateNot yet occurred (as filed)
Filing DateMarch 28, 2024
Accession Number0001996979-24-000001
Total Offering AmountIndefinite
Total Amount Sold$0 (no sales yet)
Total Investors0 (no sales yet)
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$0 (to BAIN CAPITAL DISTRIBUTORS, LLC)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MA
Amendment CountOriginal filing only

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

DMarch 28, 2024

In the Terminal

Filing events

1

latest Mar 28, 2024

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

pre_sale

Latest event New filer · Mar 28, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the Bain Capital Life Sciences Fund family: 4 vehicles across 3 generations · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • The dated record: 15 facts with source, effective date and capture date, viewable as AltStreet knew them on any past day
  • 1 filing event with values and deltas, latest 2024-03-28, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Regulatory Activity

Filing events on this entity detected by AltStreet's EDGAR monitoring.

Aug 2026Exchange Act filing
SEC.gov
Aug 2026Exchange Act filing
SEC.gov

Signal analysis reserved for subscribers

Severity grading, value-change deltas, and analyst notes on these filings ship in the AltStreet newsletter and the Pro terminal.

Get the signal feed

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

ADAM KOPPEL

Executive Officer · BOSTON, MA

JEFFREY SCHWARTZ

Executive Officer · BOSTON, MA

RICKY SUN

Executive Officer · BOSTON, MA

ANDREW HACK

Executive Officer · BOSTON, MA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

BAIN CAPITAL DISTRIBUTORS, LLCCRD 175456 on BrokerCheck

Associated broker-dealer: None · BOSTON, MA · Soliciting in all states

Questions About Bain Capital Life Sciences Fund IV, L.P.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Bain Capital Life Sciences Fund IV, L.P.?

Bain Capital Life Sciences Fund IV, L.P. is a Delaware limited partnership that filed a Form D with the SEC on March 28, 2024 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests. AltStreet links the issuer to Bain Capital Life Sciences Fund IV, L.P..

Is Bain Capital Life Sciences Fund IV, L.P. legit?

AltStreet does not rate legitimacy; it reports the public record. Bain Capital Life Sciences Fund IV, L.P. filed a Form D with the SEC on March 28, 2024 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to Bain Capital Life Sciences Fund IV, L.P., which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Bain Capital Life Sciences Fund IV, L.P. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Bain Capital Life Sciences Fund IV, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Bain Capital Life Sciences Fund IV, L.P. raised?

Bain Capital Life Sciences Fund IV, L.P. reported that the first sale had not yet occurred as of the Form D filed March 28, 2024, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.

Who can invest in Bain Capital Life Sciences Fund IV, L.P.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Bain Capital Life Sciences Fund IV, L.P.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Bain Capital Life Sciences Fund IV, L.P. and how are they paid?

The Form D names BAIN CAPITAL DISTRIBUTORS, LLC (CRD 175456), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Bain Capital Life Sciences Fund IV, L.P.?

The Form D lists 4 related persons: ADAM KOPPEL, executive officer; JEFFREY SCHWARTZ, executive officer; RICKY SUN, executive officer; ANDREW HACK, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Bain Capital Life Sciences Fund IV, L.P. located?

The issuer's address on its SEC filings is 200 Clarendon Street, Boston, MA 02116. Its phone number of record is 6175162000. It is organized under the laws of Delaware.

How long is the Bain Capital Life Sciences Fund IV, L.P. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

How large is Bain Capital Life Sciences Fund IV, L.P.?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.

Claim this profile, freeVerify this entity, $480/yrPlatform verification, from $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.